Literature DB >> 23543121

Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching.

Yuanye Zhang1, Ming-Hui Chen, Joseph G Ibrahim, Donglin Zeng, Qingxia Chen, Zhiying Pan, Xiaodong Xue.   

Abstract

Motivated from a colorectal cancer study, we propose a class of frailty semi-competing risks survival models to account for the dependence between disease progression time, survival time, and treatment switching. Properties of the proposed models are examined and an efficient Gibbs sampling algorithm using the collapsed Gibbs technique is developed. A Bayesian procedure for assessing the treatment effect is also proposed. The deviance information criterion (DIC) with an appropriate deviance function and Logarithm of the pseudomarginal likelihood (LPML) are constructed for model comparison. A simulation study is conducted to examine the empirical performance of DIC and LPML and as well as the posterior estimates. The proposed method is further applied to analyze data from a colorectal cancer study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23543121      PMCID: PMC3745804          DOI: 10.1007/s10985-013-9254-8

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  8 in total

1.  Semi-parametric inferences for association with semi-competing risks data.

Authors:  Debashis Ghosh
Journal:  Stat Med       Date:  2006-06-30       Impact factor: 2.373

2.  Regression modeling of semicompeting risks data.

Authors:  Limin Peng; Jason P Fine
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

3.  Parametric likelihoods for multiple non-fatal competing risks and death.

Authors:  Y Shen; P F Thall
Journal:  Stat Med       Date:  1998-05-15       Impact factor: 2.373

4.  Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study.

Authors:  Donglin Zeng; Qingxia Chen; Ming-Hui Chen; Joseph G Ibrahim
Journal:  Biometrika       Date:  2011-12-29       Impact factor: 2.445

5.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Marc Peeters; Salvatore Siena; Yves Humblet; Alain Hendlisz; Bart Neyns; Jean-Luc Canon; Jean-Luc Van Laethem; Joan Maurel; Gary Richardson; Michael Wolf; Rafael G Amado
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

6.  The competing risks illness-death model under cross-sectional sampling.

Authors:  Micha Mandel
Journal:  Biostatistics       Date:  2009-11-23       Impact factor: 5.899

7.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

8.  Bayesian analysis of generalized odds-rate hazards models for survival data.

Authors:  Tathagata Banerjee; Ming-Hui Chen; Dipak K Dey; Sungduk Kim
Journal:  Lifetime Data Anal       Date:  2007-03-31       Impact factor: 1.429

  8 in total
  10 in total

1.  Frailty modelling approaches for semi-competing risks data.

Authors:  Il Do Ha; Liming Xiang; Mengjiao Peng; Jong-Hyeon Jeong; Youngjo Lee
Journal:  Lifetime Data Anal       Date:  2019-02-07       Impact factor: 1.588

2.  Bayesian Semi-parametric Analysis of Semi-competing Risks Data: Investigating Hospital Readmission after a Pancreatic Cancer Diagnosis.

Authors:  Kyu Ha Lee; Sebastien Haneuse; Deborah Schrag; Francesca Dominici
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2015-02-01       Impact factor: 1.864

3.  A new Bayesian joint model for longitudinal count data with many zeros, intermittent missingness, and dropout with applications to HIV prevention trials.

Authors:  Jing Wu; Ming-Hui Chen; Elizabeth D Schifano; Joseph G Ibrahim; Jeffrey D Fisher
Journal:  Stat Med       Date:  2019-11-05       Impact factor: 2.373

4.  A Bayesian multi-risks survival (MRS) model in the presence of double censorings.

Authors:  Mário de Castro; Ming-Hui Chen; Yuanye Zhang; Anthony V D'Amico
Journal:  Biometrics       Date:  2020-02-06       Impact factor: 2.571

5.  SemiCompRisks: An R Package for the Analysis of Independent and Cluster-correlated Semi-competing Risks Data.

Authors:  Danilo Alvares; Sebastien Haneuse; Catherine Lee; Kyu Ha Lee
Journal:  R J       Date:  2019-08-20       Impact factor: 3.984

6.  Hierarchical models for semi-competing risks data with application to quality of end-of-life care for pancreatic cancer.

Authors:  Kyu Ha Lee; Francesca Dominici; Deborah Schrag; Sebastien Haneuse
Journal:  J Am Stat Assoc       Date:  2016-10-18       Impact factor: 5.033

7.  Bayesian path specific frailty models for multi-state survival data with applications.

Authors:  Mário de Castro; Ming-Hui Chen; Yuanye Zhang
Journal:  Biometrics       Date:  2015-03-11       Impact factor: 2.571

8.  Kernel machine score test for pathway analysis in the presence of semi-competing risks.

Authors:  Matey Neykov; Boris P Hejblum; Jennifer A Sinnott
Journal:  Stat Methods Med Res       Date:  2016-06-02       Impact factor: 3.021

9.  Semi-Competing Risks Data Analysis: Accounting for Death as a Competing Risk When the Outcome of Interest Is Nonterminal.

Authors:  Sebastien Haneuse; Kyu Ha Lee
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-04-12

10.  Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research.

Authors:  Ina Jazić; Deborah Schrag; Daniel J Sargent; Sebastien Haneuse
Journal:  J Natl Cancer Inst       Date:  2016-07-05       Impact factor: 13.506

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.